Medical treatment of haemangiomas;Tratamiento médico de los hemangiomas

Anales del Sistema Sanitario de Navarra

Volumn 27, Issue SUPPL. 1, 2004, Pages 81-92

  Lloret, Pedro ^a,b  

^a UNIVERSITY CLINIC OF NAVARRA   (Spain)

^b Universitaria de Navarra   (Spain)

Author keywords

Expectant; Haemangioma; Medical; Regression

Indexed keywords

ALCOHOL; ALPHA2A INTERFERON; BETAMETHASONE; BLEOMYCIN; COMBRETASTATIN A1 PHOSPHATE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; LIDOCAINE; PARACETAMOL; PREDNISOLONE; PREDNISONE; TRANEXAMIC ACID; TRIAMCINOLONE ACETONIDE; VASCULOTROPIN; VINCRISTINE;

ANALGESIA; ARTIFICIAL EMBOLISM; ATTITUDE; BREATHING; CONGESTIVE HEART FAILURE; CRYOTHERAPY; CYTOTOXICITY; HEMANGIOMA; HUMAN; INTESTINE FUNCTION; KASABACH MERRITT SYNDROME; KIDNEY FUNCTION; MEDICAL DECISION MAKING; NEUROLOGIC DISEASE; NEUROTOXICITY; RADIOTHERAPY; REVIEW; SCLEROTHERAPY; SIDE EFFECT; SKIN ULCER; SWALLOWING; TREATMENT INDICATION; TREATMENT PLANNING; TUMOR GROWTH; VISION;

ADRENAL CORTEX HORMONES; ANTINEOPLASTIC AGENTS; CHILD; CHILD, PRESCHOOL; HEMANGIOMA; HUMANS; INTERFERON-ALPHA;

EID: 2442618971     PISSN: 11376627     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (77)

1. BRUCKNER AL, FRIEDEN IJ. Hemangiomas of infancy. J Am Acad Dermatol 2003; 48: 477-493.
2. LISTER WA, CAMB MD. The natural history of strawberry nevi. Lancet 1938; 1429-1434.
3. GAMPPER TJ, MORGAN RF. Vascular anomalies: hemangiomas. Plast Reconstr Surg 2002; 110: 572-585.
4. AVERY JK. Exercise best judgement to avoid suits. J Ark Med Soc 2000; 96: 440-441.
5. BENNET ML, FLEISCHER AB, CHAMLIN SL, FRIEDEN IJ. Oral corticosteroid use is effective for cutaneous hemangiomas: An evidence-based evaluation. Arch Dermatol 2001; 137: 1208-1213.
6. FOST NC, ESTERLY NB. Successful treatment of juvenile hemangiomas with prednisone. J Pedlatr 1968; 72: 351-357.
7. FOLKMAN J. Toward a new understanding of vascular proliferative disease in children. Pediatrics 1984; 74: 850-856.
8. HASAN Q, TAN ST, GUSH J, PETERS SG, DAVIS PF. Steroid therapy of a proliferating hemangioma: histochemical and molecular changes. Pediatrics 2000; 105: 117-120.
9. HASAN Q, TAN ST, XU B, DAVIS PF. Effects of five commonly used glucocorticoids on hemangioma in vitro. Clin Exp Pharmacol Physiol 2003; 30: 140-144.
10. ZWEIFACH BW, SHOU BLACK M. The influence of the adrenal cortex on the behavior of terminal vascular beds. Ann NY Acad Sci 1953; 56: 626-633.
11. SASAKI GH, PANG CY, WITTLIFF JL. Pathogenesis and treatment of infant strawberry hemangiomas: clinical and in vitro studies of hormonal effects. Plast Reconstr Surg 1984; 73: 359-368.
12. AKYUZ C, YARIS N, KUTLUK MT, BUYUKPAMUKCU M. Management of cutaneous hemangiomas: a retrospective analysis of 1.109 cases and comparison of conventional dose prednisolone with high dose methylprednisolone therapy. Pediatr Hematol Oncol 2001; 18: 47-55.
13. WILLIAMS EF, STANISLAW P, DUPREE M, MOURTZIKOS K, MIHM M, SHANNON L. Hemangiomas in infants and children: An algorithm for intervention. Arch Facial Plast Surg 2000; 2: 103-111.
14. VERMA K, VERMA KK. Infantile periocular haemangioma treated with two days in a week betamethasone oral mini pulse therapy. Indian J Pediatr 2001; 68: 355-356.
15. BOON LM, MAC DONALD DM, MULLIKEN JB. Complications of systemic corticosteroid therapy for problematic hemangioma. Plast Reconstr Surg 1999; 104: 1616-1623.
16. ENJOLRAS O, RICHÉ MC, MERLAND JJ, ESCANDA JP. Management of alarming hemangiomas in infancy. A review of 25 cases. Pediatrics 1990; 85: 491-498.
17. DINEHART SM, KINCANNON J, GERONEMUS R. Hemangiomas: Evaluation and treatment. Dermatol Surg 2001; 27: 475-485.
18. FERNÁNDEZ-VOZMEDIANO J, NIETO I. Terapéutica de los angiomas. En: Curso de actualización en Dermatología para médicos internos y residentes. Madrid. Fundación salud y comunicación 1996.
19. HU Q, LIN X, SHANG Q, DONG J, QI Z, WANG W. The determination and significance of VEGF in the serum of hemangioma patients. Zhonghua Zheng Xing Wai Ke Za Zhi 2002; 18: 98-100.
20. THEDENAT B, LEAUTE-LABREZE C, BORALEVI F, ROUL S, LABBE L, MARLIER V et al. Surveillance tensionnelle des nourrisons traites par corticotherapie generale pour un hemangioma. Ann Dermatol Venereol 2002; 129: 183-185.
21. HYAMS JS, CAREY DE. Corticosteroids and growth. J Pediatr 1980; 113: 249-253.
22. AZZOLINI A, NOUVENNE R. Nuove prospettive nella terapia degli angiomi immaturi dell'infanzia: 115 lesione trátate con infiltración intralesionali di triamcinolone acetonide. Ateneo Parmense (Acta Biomed) 1970; (Supl): 41-51.
23. KUSHNER BJ. The treatment of periorbital infantile hemangioma with intralesional corticosteroid. Plast Reconstr Surg 1985; 76: 517-524.
24. SUTULA FC, GLOVER AT. Eyelid necrosis following intralesional corticosteroid injection for capillary hemangioma. Ophtalmic Surg 1987; 18: 103-105.
25. SHORR N, SEIFF SR. Central retina artery oclusion associated with periocular corticosteroid injection for juvenile hemangioma. Ophtalmic Surg 1986; 17: 229-231.
26. ELSAS FJ, LEWIS AR. Topical treatment of perioocular capillary hemangioma. J Pediatr Ophtalmol Strabismus 1993; 30: 4-7.
27. WEBER G. The treatment of cavernous haemangioma with topical betamethasone 17 valerate. Br J Dermatol 1973; 89: 649-651.
28. WHITE CW, SONDHEIMER HM, CROACH EC, WILSON H, FAN LL. Treatment of pulmonary hemangiomatosis with recombinant interferon alfa 2 a. N Engl J Med 1989; 320: 1197-1200.
29. GREINWALD JH, BURKE DK, BONTHIUS DJ, BAUMAN NM, SMITH RJH. An update on the treatment of hemangiomas in children with interferon alfa 2 a. Arch Otolaryngol Head Nech Surg 1999; 125: 21-27.
30. RAMPINI E, RAMPINI P, OCCELLA C, BLEIDL D. Interferon alpha 2b for treatment of complex cutaneous hemangiomas of infancy: a reduced dosage schedule. Br J Dermatol 2000; 142: 189-191.
31. GARMENDIA G, MIRANDA N, BORROSO S, LONGCHONG M, MARTÍNEZ E, FERRERO J et al. Regresión of infancy hemangiomas with recombinant IFN-alpha 2b. J Interferon Cytokine Res 2001; 21: 31-38.
32. DUBOIS J, HERSHON L, CARMANT L, BELANGER S, LECLERC JM, DAVID M. Toxicity profile of interferon alfa 2 b in children: a prospective evaluation. J Pediatr 1999; 135: 782-785.
33. MACARTHUR CJ, SENDERS CW, KATZ J. The use of interferon alfa 2a for life threatening hemangiomas. Arch Otolaryngol Head Neck Surg 1995; 121: 690-693.
34. BLEI F, ISAKOFF M, DEB G. The response of parotid hemangiomas to the use of systemic interferon alfa 2a or steroids. Arch Otolaryngol Head Neck Surg 1997; 123: 841-844.
35. ANGER J, CARNEIRO RG, PINUS J, ERNESTO JM, FAIWICHOW G. The rebound effect in the treatment of complex hemangioma with interferon alpha 2 A. Rev Paul Med 1998; 116: 1826-1828.
36. BARLOW CF, PRIEBE CJ, MULLIKEN JB, BARNES PD, MAC DONALD D, FOLKMAN J et al. Spastic diplegia as a complication of interferon alfa 2 a treatment of hemangiomas of infancy. J Pediatr 1998; 132: 527-530.
37. VALENTINE AD, MEYERS CA, TALPAZ M. Treatment of neurotoxic side effects of interferon alfa with naltrexone. Cancer Invest 1995; 13: 561-566.
38. SARIHAN H, MOCAN H, YILDIZ K, ABES M, AKYAZICI R. A new treatment with bleomycin for complicated cutaneous hemangioma in children. Eur J Pediatr Surg 1997; 7: 158-162.
39. KULLENDORF CM. Efficacy of bleomycin treatment for symptomatic hemangiomas in children. Pediatr Surg Int 1997; 12: 526-528.
40. OXFORD A, BARKER A, THONELL S et al. Bleomycin therapy for cystic hygroma. J Pediatr Surg 1995; 30: 1282-1287.
41. TOZON N, SERSA G, CEMAZAR M. Electrochemotherapy: potentiation of local antitumor effectiveness of cisplatin in dogs and cats. Anticancer Res 2001; 21: 2483-2488.
42. TURNER C, GROSS S. Treatment of recurrent suprahyoid cervicofacial lymphangioma with intravenous cyclophosphamide. Am J Pediatr Hematol Oncol 1994; 16: 325-328.
43. HURVITZ SA, HURVITZ CH, SLONINSKY L, SANFORD MC. Successful treatment with cyclophosphamide of life threatening diffuse hemangiomatosis involving the liver. J Pediatr Hematol Oncol 2000; 22: 527-532.
44. GAO Q, WANG C, WEN Y, LI L, ZHANG J, HE Z, YANG Z. An experimental study on effects of pingyangmycin on vessels. Hua Xi Kou Qiang Yi Xue Za Zhi 2001; 19: 184-187.
45. WU L, SUN G. Treatment of hemangioma with an angiogenesis inhibitor pingyangmycin. Ind Pediatr 2000; 37: 636-639.
46. ZHONG G, MA Q, SHAO Z. Inner hemangioma ligation and pingyangmycin injection in hemangioma (with 30 cases report). Zhongzhua Zheng Xing Wai Ke Za Zhi 2000; 16: 133-135.
47. SHOU B, MENG Z, YANG Z, ZHANG Z, XU J. Effects of pinyangmycin, dexamethasone and sodium morrhuate injection on treatment of cavernous hemangioma in maxillofacial regions. Hua Xi Kou Qiang Yi Xue Za Zhi 2000; 18: 40-47.
48. MILLER SH, SMITH RL, SCHOCHAT SJ. Compression treatment of hemangiomas. Plast Reconstr Surg 1976; 58: 573-579.
49. KAPLAN M, PALLER AS. Clinical Pearl: use of self-adhesive, compressive wraps in the treatment of limb hemangiomas. J Am Acad Dermatol 1995; 32: 117-118.
50. MORE AM. Pressure in the treatment of giant hemangioma with purpura. Case report and observations. Plast Reconstr Surg 1964; 34: 606.
51. ZVULUNOV A, METZKER A. Hemangiomas and vascular malformations. Unapproved treatments. Clin Dermatol 2002; 20: 660-667.
52. REISCHLE S, SCHULLER-PETROVIC S. Treatment of capillary hemangiomas of early childhood with a new method of cryosurgery. J Am Acad Dermatol 2000; 42: 809-813.
53. MICHEL S, WLOTZKE U, HOHENLEUTNER U, LANDTHALER M. Laser und kryotherapie der Sauglingshamangiome in direkten Vergleich. Hautarzt 1998; 49: 192-196.
54. ESTERLY NB. Hemangiomas. En: Harper J, Oranje A, Prose N, editors. Textbook of pediatric dermatology. Oxford: Blackwell Science, 2000: 997-1016.
55. FOX H. Congenital abnormalities. En: Fox H, Storrs RS, editors. Diseases of the skin in infancy and childhood. New York: Appleton & Co, 1930: pp. 1-13.
56. OGINO I, TORIKAI K, KOBAYASI S, AIDA N, HATA M, KIGASOWA H. Radiation therapy for life- or function-threatening infant hemangioma. Radiology 2001; 218: 834-839.
57. LI F, CASSADY JR, BARNETT E. Cancer mortality following irradiation in infancy for hemangiomas. Radiology 1974; 113: 177-178.
58. BENJAMIN B. Treatment of infantile subglottic hemangioma with radioactive gold grain. Ann Otol Rhinol Laryngol 1978; 87: 18-21.
59. MIERZWA ML, BARRETT WL, GLUCKMAN JL. Radiation therapy for recurrent orbital hemangioma. Head Neck 2003; 25: 412-415.
60. WANG D. Retained copper needles for the treatment of cavernous hemangioma. Zhonghua Zheng Xing Shao Shan Wai Ke Za Zhi 1993; 9: 321-396.
61. STAINDL O. Treatment of hemangiomas of the face with magnesium seeds. Arch Otorhinolaryngol 1989; 246: 213-217.
62. BRUNELLE FO, CHAUMONT P, TEILLAC D, MANACH Y, LALLEMAND D. Facial vascular malformations in children. Conventional and digital, diagnostic and therapeutic angiography. Pediatr Radiol 1988; 18: 377-382.
63. SOEDA A, SAKAI N, IIHARA K, NAGATA I. Cobb syndrome in an infant; treatment with endovascular embolization and corticosteroid therapy: case report. Neurosurgery 2003; 52: 711-715.
64. TONNER PH, SCHOLZ J. Possible lung embolism following embolization of a hemangioma with fibrin glue. Anaesthesist 1994; 43: 614-617.
65. WINTER H, DRAGER E, STERRY W. Sclerotherapy for treatment of hemangiomas. Dermatol Surg 2000; 26: 105-108.
66. MATSUMOTO K, NAKANISHI H, KOIZUMI Y, SEIKE T, KANDA I, KUBO Y. Sclerotherapy of hemangioma with late involution. Dermatol Surg 2003; 29: 668-671.
67. HEMAL AK, ARON M, WADHWA SN. Intralesional sclerotherapy in the management of hemangiomas of the glans penis. J Urol 1998; 159: 415-417.
68. KIM HJ, COLOMBO M, FRIEDEN IJ. Ulcerated hemangiomas: clinical characteristics and response to therapy. J Am Acad Dermatol 2001, 962-972.
69. SARKAR M, MULLIKEN JB, KOZAKEWICH HPW, ROBERTSON RL, BURROWS PE. Thrombocytopenic coagulopathy (Kasabach-Merritt phenomenon) is associated with Kaposiform hemangioendothelioma and not with common infantile hemangioma. Plast Reconstr Surg 1977; 100: 1377-1386.
70. PEREZ-PAYAROLS J, PARDO-MASFERRER J, GOMEZ-BELLVERT C. Treatment of life-threatening infantile hemangiomas with vincristine. N Engl J Med 1995; 333: 69.
71. DE PROST Y, TEILLAC D, BODEMER C, ENJOLRAS O, NIHOUL-FEKETE C, DE PROST D. Successful treatment of Kasabach-Merritt syndrome with pentoxifylline. J Am Acad Dermatol 1991; 25: 854-855.
72. ILLUM N, KARLSMARK T, SVEJGAARD E, ULLMAN S, YSSING M. Ulcerated haemangioma successfully treated with interferon alfa-2b and topical granulocyte-macrophage colony-stimulating factor. Dermatology 1995; 191: 315-317.
73. MARTINEZ MI, SÁNCHEZ-CARPINTERO I, NORTH PE, MIHM MC JR. Infantile hemangioma: Clinical resolution with 5% imiquimod cream. Arch dermatol 2002; 138: 881-884.
74. SUGARMAN JL, MAURO TM, FRIEDEN IJ. Treatment of an ulcerated hemangioma with recombinant platelet-derived growth factor. Arch Dermatol 2002; 138: 314-316.
75. JURKLIES B, ANASTASSIOU G, ORTMANS S, SCHULER A, SCHILLING H, SCHMIDT-ERFURTH U et al. Photodynamic therapy using verteporfin in circumscribed choroidal haemangioma. Br J Ophtalmol 2003; 87: 84-89.
76. ATALAY M, GORDILLO G, ROY S, ROVIN B, BAGCHI D, BAGCHI M et al. Anti-angiogenic property of edible berry in a model of hemangioma. FEBS Lett 2003; 544: 252-257.
77. LIEKENS S, ANDREI, G, VANDEPUTFE M, DE CLERCQ E, NEYTS J. Potent inhibition of hemangioma formation in rats by the acyclic nucleoside phosphonate analogue cidofovir. Cancer Res 1998; 58: 2562-2567.